The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus
Authors:
- Tomislav BozekTBTomislav Bozek
- Antonela BlazekovicABAntonela Blazekovic
- Matea Nikolac PerkovicMPMatea Nikolac Perkovic
- Kristina Gotovac JercicKristina Gotovac Jercic
- Aleksandra SustarASAleksandra Sustar
- Lea Smircic-DuvnjakLSLea Smircic-Duvnjak
- Tiago F. OuteiroTiago F. Outeiro
- Nela PivacNela Pivac
- Fran BoroveckiFBFran Borovecki
Open Access
- 4 December 2017
- journal article
- research article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 9 (1) , 97
Abstract
Type II diabetes is an important health problem with a complex connection to obesity, leading to a broad range of cardiovascular complications. Insulin therapy often results in weight gain and does not always ensure adequate glycemic control. However, previous studies reported that insulin detemir is an efficient long-acting insulin with a weight sparing effect. The aim of this study was to determine the association of catechol O-methyltransferase (COMT) Val108/158Met and dopamine-beta-hydroxylase (DBH) 1021C/T polymorphisms with the effectiveness of insulin detemir in achieving glucose control and body weight control. Participants and methods: This 52-week observational study included 185 patients with inadequate glycemic control treated with premix insulin analogues, which were replaced with insulin aspart and insulin detemir, and 156 healthy controls. After DNA isolation from blood samples, genotyping of DBH-1021C/T polymorphism (rs1611115) and COMT Val108/158Met polymorphism (rs4680) was performed. Our results confirmed that insulin detemir did not lead to weight gain. The most significant finding was that A carriers (the combined AG and AA genotype) of the COMT Val108/158Met achieved significantly better hemoglobin A1c (HbA1c) values compared to patients carrying GG genotype. No association between DBH-1021C/T genotypes and weight and/or glucose control was detected in diabetes patients or in healthy control subjects. This study showed that the presence of one or two A allele of the COMT Val108/158Met was associated with improved glycemic response, and with a better response to insulin detemir therapy in patients with type II diabetes, separating them as best candidates for detemir therapy.Keywords
Funding Information
- Hrvatska Zaklada za Znanost (HRZZ 9386)
- TFO is supported by the DFG Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB).
This publication has 53 references indexed in Scilit:
- Genetics of Human Cardiovascular DiseaseCell, 2012
- Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 DiabetesDiabetes Care, 2011
- Cardiovascular Disease Risk Factors, Type 2 Diabetes Mellitus, and the Framingham Heart StudyTrends in Cardiovascular Medicine, 2010
- Benefits of moderate weight loss in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2010
- Euglycemic Infusion of Insulin Detemir Compared With Human Insulin Appears to Increase Direct Current Brain Potential Response and Reduces Food Intake While Inducing Similar Systemic EffectsDiabetes, 2010
- Polymorphisms of Serotonin Receptor 2A and 2C Genes and COMT in Relation to Obesity and Type 2 DiabetesPLOS ONE, 2009
- Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trialHuman Genetics, 2007
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006
- Obesity is Associated with Genetic Variants That Alter Dopamine AvailabilityAnnals of Human Genetics, 2006
- Dopamine β-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variationHuman Genetics, 1998